BTIG keeps Buy rating on Avalo Therapeutics with $10 price target
BTIG maintained its Buy rating on Avalo Therapeutics with a $10 target, implying 34.2% upside from the Oct 22 close, per TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
BTIG analysts kept their Buy rating on Avalo Therapeutics shares and set a price target of $10. That target points to roughly 34.2% upside from the October 22 close of $7.45. The information comes from TradingView, which cites data provided by Benzinga.
The analyst note highlights the lead asset, Abdakibart, which showed statistically significant improvements in key metrics such as HiSCR75 in Phase 2 trials. Its safety results were comparable to placebo. The note also says the hidradenitis suppurativa market is still underpenetrated, with only a couple of treatment classes available. BTIG sees the drug's differentiated mechanism and less frequent dosing as supports for its commercial potential.
why it matters
For markets this is a routine update on a single stock. One analyst's rating usually has limited influence on a small biotech company's shares. Newer clinical data or regulatory decisions would be a bigger signal, and neither is mentioned in this text.
tags
instruments
sources
- BTIG maintains Buy rating on Avalo Therapeutics, $10 price target — TradingView, 23 October 2026 at 09:41 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗